GEN1E LIFESCIENCES INC.
AI-driven drug discovery and development platform for identifying and optimizing therapeutic candidates
New patent ·
- Sector
- Biotech
- Headquarters
- Palo Alto, CA
- Founded
- 2018
- Latest Form D
- $5.5M, Dec 2025
- Total capital
- $23.3M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $22.5M
- 2 Form D · last Dec 2025
- 10 months since last filing
- Federal contracts
- $749K
- 1 award · Health and Human S
- Rank in Biotech#209 of 4373
- Granted patents
- 11
- 17 pending · first 2022
- Rank in peer group#22 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$5.5M
- Federal contractHealth and Human S · GEN1E - This Contract Will Provide Support To GEN1E Lifesciences Inc. (GEN1E), A US Company, For The Advancement Of Patient Stratification And Endotyping Approaches As It Develops GEN-1124, A Novel Treatment For Acute Respiratory Distress Syndrome (a$749K
- Private capital raisedForm D · SEC · 1st filing$17M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#22 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Ritu LalResearcherExecutive Officer, DirectorLinked by 1 patent
- Alan LevyDirectorNamed in SEC Form D filings
- Dr. Alan LevyDirectorNamed in SEC Form D filings
- Francois NaderDirectorNamed in SEC Form D filings
- Noor KamruddinDirectorNamed in SEC Form D filings
- Soujanya BhumkarDirectorNamed in SEC Form D filings
What it has protected
USPTO · 11 granted of 28- New patentP38ALPHA Mitogen-activated Protein Kinase InhibitorsUSPTOUS 12,753,184
- PendingModulators Of Extracellular Signal-regulated KinaseUSPTOApplication 19551404
- GrantedModulators Of Extracellular Signal-regulated KinaseUSPTOUS 12,595,243
Show all 28 patent records
- P38ALPHA Mitogen-activated Protein Kinase InhibitorsOct 6, 2026 · US 12,753,184Granted
- Modulators Of Extracellular Signal-regulated KinaseJul 9, 2026 · Application 19551404Pending
- Modulators Of Extracellular Signal-regulated KinaseApr 7, 2026 · US 12,595,243Granted
- Crystalline CHLORO-N-(4-(MORPHOLINOMETHYL)PHENYL)BENZAMIDE And Crystalline Hydrochloride SaltOct 30, 2025 · Application 18806836Pending
- Substituted Naphthyl P38ALPHA Mitogen-activated Protein Kinase InhibitorsAug 28, 2025 · Application 19206808Pending
- Crystalline 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-SULFONAMIDE Di-hydrochloride Di-hydrateJul 31, 2025 · Application 19068635Pending
- Substituted Naphthyl P38ALPHA Mitogen-activated Protein Kinase InhibitorsJun 17, 2025 · US 12,331,024Granted
- Crystalline 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-SULFONAMIDE Di-hydrochloride Di-hydrateApr 8, 2025 · US 12,269,792Granted
- Machine Learning Methods And Systems For Acute Respiratory Distress Syndrome Patient Sub-phenotypingMar 20, 2025 · Application 18890241Pending
- Crystalline CHLORO-N-(4-(MORPHOLINOMETHYL)PHENYL)BENZAMIDE And Crystalline Hydrochloride SaltOct 15, 2024 · US 12,116,353Granted
- P38ALPHA Mitogen-activated Protein Kinase InhibitorsJun 6, 2024 · Application 18425036Pending
- Substituted Naphthyl P38ALPHA Mitogen-activated Protein Kinase InhibitorsMay 7, 2024 · US 11,976,049Granted
- P38ALPHA Mitogen-activated Protein Kinase InhibitorsMar 12, 2024 · US 11,926,635Granted
- Substituted Naphthyl P38ALPHA Mitogen-activated Protein Kinase InhibitorsJan 17, 2023 · US 11,555,020Granted
- P38ALPHA Mitogen-activated Protein Kinase InhibitorsSep 13, 2022 · US 11,440,918Granted
- Crystalline 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-SULFONAMIDE Di-hydrochloride Di-hydrateJul 19, 2022 · US 11,390,581Granted
- P38ALPHA Mitogen-activated Protein Kinase InhibitorsMar 29, 2022 · US 11,286,260Granted
- Substituted Naphthyl P38ALPHA Mitogen-activated Protein Kinase InhibitorsApplication PCTUS2022021181Pending
- Crystalline 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHY)PHENYL) NAPHTHALENE-1-SULFONMIDE Di-hydrochloride Di-hydrateApplication PCTUS2021055950Pending
- P38ALPHA Mitogen-activated Protein Kinase InhibitorsApplication PCTUS2021032487Pending
- Substituted Naphthyl P38ALPHA Mitogen-activated Protein Kinase InhibitorsApplication 63164664Pending
- Crystalline 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-SULFONAMIDE Di-hydrochloride Di-hydrateApplication 63106991Pending
- P38ALPHA Mitogen-activated Protein Kinase InhibitorsApplication 63026466Pending
- Machine Learning Methods And Systems For Acute Respiratory Distress Syndrome Patient Sub-phenotypingApplication 63539246Pending
- Inhibitors Of Extracellular Signal-regulated KinaseApplication PCTUS2024052017Pending
- Machine Learning Methods And Systems For Acute Respiratory Distress Syndrome Patient Sub-phenotypingApplication PCTUS2024047474Pending
- Crystalline CHLORO-N-(4-(MORPHOLINOMETHYL)PHENYL)BENZAMIDE And Crystalline Hydrochloride SaltApplication PCTUS2025023670Pending
- Modulators Of Extracellular Signal-regulated KinaseApplication PCTUS2024051971Pending
Related companies, and why
- Rigel PharmaceuticalsSimilar federal contract value in Biotech · $750K in contracts
- GRYPHON BIO INCSimilar federal contract value in Biotech · $749K in contracts
- RenBio, Inc.Similar federal contract value in Biotech · $749K in contracts
- GALEN BIOTECHNOLOGIES, LLCSimilar federal contract value in Biotech · $727K in contracts
- KromaTiD, Inc.Similar federal contract value in Biotech · $726K in contracts
- APHIOS CORPORATIONSimilar federal contract value in Biotech · $723K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .